Supplementary Figure S5 from IL4/IL13 Inhibition via Dupilumab Reduces Malignant T-cell Proliferation and Promotes Antitumor Immunity in Sézary Syndrome

Figure S5. B tSNE1 15 10 5 0 tSNE1 cluster 0-1 0 log2 fold change 25 20 1 15 10 5 0 PF46 PF47 PF48 PF49 PF50 cluster 0 1 2 3 4 cluster 1-2-1 0 1 2 log2 fold change C CD14 FLT3 avg. expr. tSNE1 E 100% 0 2 4 75% 50% 25% 0% 0 1 2 3 4 cluster log2FC p-value p–value and log2 FC NS 5 0 PF46 PF47 PF48 PF49 PF50 cluster 2-2-1 log2 fold change 0 1 2 avg. expr. tSNE 1 F 3 2 1 0 2 1 IL13RA1 1 0 2 3 IL4R 0 10 5 0 0 1 2 cluster cluster 3 3 4-4-2 0 2 log2 fold change 4 Effect of Dupilumab (REGN688) on healthy control myeloid cells.